The latest update is out from Theriva Biologics (TOVX).
Theriva Biologics, Inc. has revealed promising preclinical data showing the enhanced effectiveness of its lead product, VCN-01, in combination with liposomal irinotecan, in treating human pancreatic cancer in mice. This combination therapy not only inhibited tumor growth significantly but also demonstrated a favorable safety profile. These findings, which highlight a potential advancement in pancreatic cancer treatment, are set to be showcased at the ASGCT 27th Annual Meeting.
For a thorough assessment of TOVX stock, go to TipRanks’ Stock Analysis page.
